title: Copper(II) complexes of a nonsteroidal anti-inflammatory drug niflumic acid. Synthesis, crystal structure of tetrakis-mu-(2-[3-(trifluoromethyl) phenyl]aminonicotinato)bis(dimethylsulfoxide)-dicopper(II) complex at 190 K. Anti-inflammatory properties.
abstract: The synthesis and characterization of three complexes with a potent nonsteroidal anti-inflammatory drug niflumic acid {2-[3-(trifluoromethyl)phenyl]aminonicotinic acid} with formula [Cu(niflumato)2L] (L = H2O, DMSO = dimethylsulfoxide, DMF = N,N-dimethylformamide) were investigated. The crystal and molecular structure of the {Cu(niflumato)2(DMSO)}2 was reported. Crystallographic data are as follows: monoclinic system, space group P2(1)/n, Z = 2, a = 11.1318(8), b = 17.513(2), c = 15.336(1) A, beta = 103.316(8) degrees, V = 2909.4(4) A3. The structure was refined to R = 0.030 and wR = 0.037 for 3702 reflections with I > sigma (I). It consists of centrosymmetric binuclear units with the Cu-Cui (symmetry code i: 1-x, -y, 1-z) distance between two centrosymmetrically related ions of 2.6272(5) A. Each Cu(II) ion in [Cu2(DMSO)2(mu-niflumato)4] is coordinated to an apical dimethylsulfoxide O atom on the one hand and to the equatorial carbonyl and carboxylic O atoms of two crystallographically independent niflumate moieties and their centrosymmetric counterparts on the other hand. In spite of the low-temperature (190 K) crystal measurements, one L-CF3 grouping exhibits some disorder. The biological activities of these complexes were compared to that of niflumic acid. Niflumic acid and its various copper complexes significantly inhibited polymorphonuclear leukocyte (PMNL) oxidative metabolism, as assessed by chemiluminescence and O2- generation measurement. This effect was dose-dependent. All copper complexes exerted a similar inhibiting effect which was always significantly higher than that exerted by the parent drug.
authors.affiliation: Gustaf H. Carlson School of Chemistry, Clark University, Worcester, MA 01610, USA.
authors.forename: F T
authors.initials: FT
authors.lastname: Greenaway
authors.forename: E
authors.initials: E
authors.lastname: Riviere
authors.forename: J J
authors.initials: JJ
authors.lastname: Girerd
authors.forename: X
authors.initials: X
authors.lastname: Labouze
authors.forename: G
authors.initials: G
authors.lastname: Morgant
authors.forename: B
authors.initials: B
authors.lastname: Viossat
authors.forename: J C
authors.initials: JC
authors.lastname: Daran
authors.forename: M
authors.initials: M
authors.lastname: Roch Arveiller
authors.forename: N H
authors.initials: NH
authors.lastname: Dung
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000737:chemistry* / Q000494:pharmacology; D003300:Copper / Q000737:chemistry*; D018360:Crystallography, X-Ray; D066298:In Vitro Techniques; D008163:Luminescent Measurements; D008297:Male; D008958:Models, Molecular; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism; D009544:Niflumic Acid / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D009942:Organometallic Compounds / Q000737:chemistry* / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013481:Superoxides / Q000378:metabolism
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D009942:Organometallic Compounds; C403275:bis(dimethylsulfoxide)bis(2-(3-(trifluoromethyl)phenyl)aminonicotinic acid)copper(II); D013481:Superoxides; D009544:Niflumic Acid; D003300:Copper